TRVN - Trevena, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0300
0.0000 (0.00%)
As of 9:30AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0300
Open1.0300
Bid1.0100 x 800
Ask0.0000 x 3200
Day's Range1.0300 - 1.0300
52 Week Range0.3820 - 3.5780
Volume2,507
Avg. Volume863,822
Market Cap95.124M
Beta (3Y Monthly)4.62
PE Ratio (TTM)N/A
EPS (TTM)-0.3380
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.75
Trade prices are not sourced from all markets
  • GlobeNewswire21 days ago

    Trevena Appoints Barry Shin as Chief Financial Officer

    Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with Central Nervous System (CNS) conditions, today announced the appointment of Barry Shin as Chief Financial Officer. Mr. Shin joins Trevena with extensive experience advising biopharmaceutical companies through merger and acquisition (M&A) and financing transactions.  He was previously Managing Director in the Healthcare Investment Banking Group at Mizuho Securities.  Prior to joining Mizuho Securities, he was a Managing Director in Guggenheim Securities’ Healthcare Investment Banking Group from 2012 to 2017.  From 2005 to 2012, he served in positions of increasing responsibility within the Healthcare Investment Banking Group of Piper Jaffray.  From 2001 to 2005, he advised healthcare and technology companies in financing and M&A transactions as a corporate attorney.  Mr. Shin received a B.Sc.

  • GlobeNewswire24 days ago

    Trevena Announces Publication of APOLLO-2 Results in Pain Practice

    The publication: “APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the µ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty”, with lead author, Neil Singla, M.D., CEO of Lotus Clinical Research, is available online at https://doi.org/10.1111/papr.12801.

  • Trevena 'on track' to resubmit opioid pain medicine application early next year
    American City Business Journals28 days ago

    Trevena 'on track' to resubmit opioid pain medicine application early next year

    The Chester County biopharmaceutical company said it has initiated a safet study requested by the FDA.

  • GlobeNewswire28 days ago

    Trevena Announces Initiation of Healthy Volunteer Study for Oliceridine

    CHESTERBROOK, Pa., June 20, 2019 -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of.

  • Business Wire2 months ago

    TREVENA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Trevena, Inc. - TRVN

    Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Trevena, Inc. (TRVN). On November 7, 2017, the Company reported that it had submitted a New Drug Application (“NDA”) for Oliceridine, its lead product candidate. On November 2, 2018, the Company disclosed that it received a response from the Food and Drug Administration (“FDA”) denying the NDA for Oliceridine due to inadequate data to support approval.

  • GlobeNewswire2 months ago

    Trevena to Participate in Upcoming Conferences in June 2019

    CHESTERBROOK, Pa., May 29, 2019 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of TRVN earnings conference call or presentation 13-May-19 12:00pm GMT

    Q1 2019 Trevena Inc Earnings Call

  • Associated Press2 months ago

    Trevena: 1Q Earnings Snapshot

    On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 6 cents. The company's shares closed at $1.55. A year ago, they were trading at $1.98. _____ This story was generated ...

  • GlobeNewswire2 months ago

    Trevena Reports First Quarter 2019 Results

    — Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to.

  • Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
    Zacks3 months ago

    Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

    During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

  • Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
    Zacks3 months ago

    Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

    Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

  • Introducing Trevena (NASDAQ:TRVN), The Stock That Tanked 83%
    Simply Wall St.3 months ago

    Introducing Trevena (NASDAQ:TRVN), The Stock That Tanked 83%

    Trevena, Inc. (NASDAQ:TRVN) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share...

  • GlobeNewswire3 months ago

    AMAG Pharmaceuticals Appoints New Members to Board of Directors

    “We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.

  • Trevena (TRVN) Gains As Market Dips: What You Should Know
    Zacks4 months ago

    Trevena (TRVN) Gains As Market Dips: What You Should Know

    Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of TRVN earnings conference call or presentation 13-Mar-19 12:00pm GMT

    Q4 2018 Trevena Inc Earnings Call

  • Will Trevena Continue to Surge Higher?
    Zacks4 months ago

    Will Trevena Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in Trevena.

  • Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
    Zacks4 months ago

    Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia

    Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

  • ACCESSWIRE4 months ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
    Zacks4 months ago

    Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?

    Is (TRVN) Outperforming Other Medical Stocks This Year?

  • Trevena says it has 'clear path' to resubmit application for experimental pain medicine
    American City Business Journals4 months ago

    Trevena says it has 'clear path' to resubmit application for experimental pain medicine

    The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.

  • PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
    Zacks4 months ago

    PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y

    PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.

  • Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
    Zacks4 months ago

    Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why

    Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.

  • Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
    Zacks4 months ago

    Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up

    Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.

  • Associated Press4 months ago

    Trevena: 4Q Earnings Snapshot

    On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...

  • GlobeNewswire4 months ago

    Trevena Reports Fourth Quarter and Full Year 2018 Results

    — Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA —  — Successful fundraising extends cash runway into 3Q 2020 —Company to.